Despite being the hallmark of cancer that is responsible for the highest number of deaths,
very little is known about the biology of metastasis. Metastatic disease typically manifests …

Human epidermal growth factor receptor 2 (HER2) is overexpressed and/or amplified in
approximately 20% of breast cancers, conferring an aggressive tumor behavior but also an …

Breast cancer has become one of the top five commonest causes of cancer death. The use
of ferroptosis to induce the generation of reactive oxygen species (ROS) in cancer cells …

Importance It is estimated that up to 50% of patients with ERBB2 (HER2)-positive metastatic
breast cancer (MBC) will develop brain metastases (BMs), which is associated with poor …

In the later-line setting or for patients with PD-L1-negative tumors, immunotherapy-based
regimens remain ineffective against advanced triple-negative breast cancer (TNBC). In this …

Objectives Breast cancer (BC) is the most common cancer in women worldwide, and
neoadjuvant chemotherapy (NAC) is considered the standard of treatment for most patients …

Sacituzumab govitecan (SG), the first antibody–drug conjugate (ADC) approved for triple-
negative breast cancer, incorporates the anti-TROP2 antibody hRS7 conjugated to a …

In the current era of precision medicine, the identification of genomic alterations has
revolutionised the management of patients with solid tumours. Recent advances in the …

The management of human epidermal growth factor receptor (HER2)–positive breast cancer
(BC) has rapidly evolved over the last 20 years. Major advances have led to US Food and …

Background Palbociclib added to endocrine therapy improves progression-free survival in
hormone-receptor-positive, HER2-negative, metastatic breast cancer. The PALLAS trial …